Journal Scans
Total Therapy 3 for Multiple Myeloma: Prognostic Implications of Cumulative Dosing and Premature Discontinuation of VTD Maintenance Components, Bortezomib, Thalidomide and Dexamethasone, Relevant to All Phases of Therapy
Drug Dosing in Total Therapy 3 for Multiple Myeloma
F van Rhee, J Szymonifka, E Anaissie, B Nair, S Waheed, Y Alsayed, N Petty, JD Shaughnessy Jr, A Hoering, J Crowley, B Barlogie
20100425
2010 May 25
Blood
Total Therapy 3 for Multiple Myeloma: Prognostic Implications of Cumulative Dosing and Premature Discontinuation of VTD Maintenance Components, Bortezomib, Thalidomide and Dexamethasone, Relevant to All Phases of Therapy
Blood. 2010 May 25;[Epub Ahead of Print], F van Rhee, J Szymonifka, E Anaissie, B Nair, S Waheed, Y Alsayed, N Petty, JD Shaughnessy Jr, A Hoering, J Crowley, B Barlogie
TAKE-HOME MESSAGE
Abstract
Abstract
The impact of cumulative dosing and premature drug discontinuation (PMDD) of bortezomib (V), thalidomide (T) and dexamethasone (D) on overall survival (OS), event-free survival (EFS), time to next therapy (TNT) and post-relapse survival (PRS) in Total Therapy 3 were examined, employing time-dependent methodology, relevant to induction, peri-transplantation, consolidation and maintenance phases. Univariately, OS and EFS were longer in case higher doses were used of all agents during induction, consolidation...
